See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $250B | 3.9x | 8.6x | |
| $193B | 3.1x | 7.7x | |
| $133B | 2.5x | 8.6x | |
| $115B | 2.7x | 8.1x | |
| $65.6B | 4.2x | 12.4x | |
| $50.9B | 6.2x | 20.9x | |
| $10.9B | 3.6x | -8.6x | |
| $9.3B | n/a | n/a | |
| $8.9B | 5.0x | -83.1x | |
| $7.0B | 7.4x | 25.3x | |
| $6.7B | 3.2x | -2.1x | |
| $4.6B | 10.6x | 31.8x | |
| $4.4B | n/a | n/a | |
| $3.8B | 5.6x | 15.5x | |
| $3.5B | 11.2x | 70.2x | |
| $3.0B | 17603.7x | n/a | |
| $2.8B | 6.6x | 22.2x | |
| $2.6B | 7.4x | 27.5x | |
| $2.6B | n/a | n/a | |
| $2.5B | 6.2x | -75.9x | |
| $2.3B | 23.5x | n/a | |
| $2.1B | 2.1x | 5.9x | |
| $2.0B | 9.1x | -65.5x | |
| $1.8B | 7.3x | -4.7x | |
| $1.7B | 10.6x | 11.6x | |
| $1.6B | n/a | n/a | |
| $1.5B | 7.8x | 25.3x | |
| $1.4B | 7.5x | 18.6x | |
| $1.4B | 7.9x | 26.6x | |
| $1.3B | 166.3x | -6.0x | |
| $1.3B | n/a | n/a | |
| $1.2B | 8.3x | 13.7x | |
| $1.0B | 308.0x | -4.1x | |
| $1.0B | 30.8x | -29.5x | |
| $996M | 19.9x | -6.6x | |
| $959M | 2.9x | 34.1x | |
| $920M | 3.9x | 12.6x | |
| $911M | 349.2x | -6.1x | |
| $909M | 5.7x | 11.0x | |
| $805M | 3.9x | -21.9x | |
| $775M | 5.5x | -9.3x | |
| $768M | 11.6x | -4.5x | |
| $758M | 4.1x | n/a | |
| $709M | 8.5x | -33.9x | |
| $681M | 3.7x | -6.4x | |
| $661M | 5767.0x | n/a | |
| $658M | 0.6x | 2.2x | |
| $579M | n/a | n/a | |
| $579M | 6.4x | -94.2x | |
| $545M | n/a | n/a | |
| $508M | 179.9x | -25.9x | |
| $500M | n/a | n/a | |
| $495M | n/a | -7.8x | |
| $463M | 509.1x | -1.5x | |
| $431M | n/a | n/a | |
| $423M | 1.9x | n/a | |
| $416M | 86.6x | n/a | |
| $389M | 25.3x | -0.7x | |
| $354M | 2.0x | 8.4x | |
| $352M | 18.0x | -1213.7x | |
| $329M | 6.9x | -4.6x | |
| $316M | 350178.5x | -12.0x | |
| $296M | n/a | n/a | |
| $293M | 1.4x | 7.2x | |
| $206M | 196192.0x | -8.2x | |
| $204M | 19.4x | -5.4x | |
| $201M | 22.9x | n/a | |
| $193M | 1.1x | n/a | |
| $177M | n/a | -4.3x | |
| $144M | 2.6x | 12.9x | |
| $142M | n/a | n/a | |
| $140M | n/a | n/a | |
| $140M | n/a | n/a | |
| $135M | 36.1x | -7.9x | |
| $131M | n/a | n/a | |
| $129M | n/a | n/a | |
| $127M | n/a | n/a | |
| $117M | n/a | n/a | |
| $112M | n/a | n/a | |
| $111M | n/a | -0.6x | |
| $110M | n/a | -4.9x | |
| $109M | n/a | -3.2x | |
| $108M | n/a | n/a | |
| $107M | n/a | n/a | |
| $107M | 5995.5x | -0.5x | |
| $101M | n/a | -0.6x | |
| $99.1M | 22833.2x | -0.5x | |
| $98.3M | 16.5x | n/a | |
| $98.0M | n/a | n/a | |
| $93.2M | n/a | n/a | |
| $83.4M | 8.6x | n/a | |
| $82.8M | 0.7x | 4.3x | |
| $74.8M | 7.4x | n/a | |
| $70.4M | n/a | n/a | |
| $67.0M | 9.6x | n/a | |
| $66.6M | n/a | n/a | |
| $63.9M | 607.0x | n/a | |
| $61.3M | 20.4x | -1.6x | |
| $56.2M | n/a | n/a | |
| $42.7M | n/a | n/a | |
| $38.0M | 21.5x | -0.7x | |
| $36.0M | 113.0x | n/a | |
| $34.4M | n/a | -0.4x | |
| $32.0M | n/a | -0.8x | |
| $31.8M | n/a | n/a | |
| $30.9M | 4.0x | n/a | |
| $27.4M | 2022.1x | -0.8x | |
| $26.0M | n/a | n/a | |
| $24.3M | 96.1x | n/a | |
| $23.7M | n/a | n/a | |
| $18.9M | n/a | -0.2x | |
| $17.8M | 8.2x | n/a | |
| $13.6M | 300.9x | n/a | |
| $13.4M | 0.2x | -0.1x | |
| $13.4M | 5.0x | n/a | |
| $9.9M | 3.9x | n/a | |
| $8.2M | n/a | n/a | |
| $6.8M | 6.9x | -0.5x | |
| $5.8M | n/a | n/a | |
| $5.2M | 4.0x | -0.2x | |
| $1.7M | 0.6x | -0.1x | |
| $32K | n/a | n/a | |
| -$1.6M | -0.3x | n/a | |
| -$21.6M | -2.8x | 0.1x | |
| -$27.8M | -0.4x | 0.1x | |
| -$30.9M | -937.6x | n/a | |
| -$35.9M | n/a | 0.3x | |
| -$41.2M | -20.9x | n/a | |
| -$46.0M | -0.4x | n/a | |
| -$53.8M | -5.8x | 0.4x | |
| -$65.8M | n/a | n/a | |
| -$73.9M | -2.1x | n/a | |
| -$77.4M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies